DRUG-COATED BALLOON ANGIOPLASTY VERSUS DRUG-ELUTING STENT IMPLANTATION FOR THE TREATMENT OF BARE-METAL AND DRUG-ELUTING STENT RESTENOSIS: RESULTS FROM THE DAEDALUS STUDY

1D Giacoppo, 2F Alfonso, 3A Kastrati, 4RA Byrne.
1Cardiovascular Research Institute (CVRI) Dublin, Mater Private Hospital, Dublin, Ireland; 2Department of Cardiology, Hospital Universitario de La Princesa, Madrid, Spain; 3Department of Cardiovascular Diseases, German Heart Centre, Munich, Germany; 4School of Pharmacy and Biomolecular Sciences, RCSI University of Medicine and Health Sciences, Dublin, Ireland

Background In patients with coronary in-stent restenosis (ISR) requiring re-intervention, it is unclear if the choice of treatment strategy depends on whether the restenotic stent was a bare-metal stent (BMS) or a drug-eluting stent (DES).

Objectives We aimed to assess the comparative efficacy and safety of the two most frequently used treatments – angioplasty with drug-coated balloon (DCB) and repeat stenting DES – in patients with BMS- and DES-ISR.

Methods The DAEDALUS study was a pooled analysis of individual patient data from all 10 existing randomized clinical trials comparing DCB angioplasty vs. repeat DES implantation for the treatment of coronary ISR. In this prespecified analysis, patients were stratified according to BMS- vs. DES-ISR, and treatment assigned. The primary efficacy endpoint was target lesion revascularization (TLR) at 3 years. The primary safety endpoint was a composite of all-cause death, myocardial infarction, or target lesion thrombosis at 3 years. Primary analysis was performed by Cox mixed-effects models accounting for the trial of origin. Secondary analyses included non-parsimonious multivariable adjustment accounting also for multiple lesions per patient and two-stage analyses.

Results A total of 710 patients with BMS-ISR (722 lesions) and 1248 with DES-ISR (1377 lesions) were included. In patients with BMS-ISR, no significant difference between treatments was observed in terms of primary efficacy (9.2% vs. 10.2%; HR 0.83, 95% CI 0.51–1.37) and safety endpoints (8.7% vs. 7.5%; HR 1.13, 95% CI 0.65–1.96); results of secondary analyses were consistent. In patients with DES-ISR, the risk of the primary efficacy endpoint was only numerically lower (9.5% vs. 13.3%; HR 0.69, 95% CI 0.47–1.00) and interaction was not significant (p=0.146); results of secondary analyses were consistent. The risk of TLR was lower in BMS- vs. DES-ISR (9.7% vs. 17.0%; HR 0.57, 95% CI 0.42–0.74), while safety was not significantly different between ISR types.

Conclusions At 3-year follow-up, DCB angioplasty and repeat stenting with DES are similarly effective and safe in the treatment of BMS-ISR, while DCB angioplasty is significantly less effective than repeat DES implantation in the treatment DES-ISR without statistically significant differences in safety endpoints. Overall, DES-ISR is associated with higher rates of treatment failure and similar safety compared with BMS-ISR.

BLOOD PRESSURE REDUCTION AFTER CATHETER-BASED RENAL DENERVATION IN THE ABSENCE OF ANTIHYPERTENSIVE MEDICATIONS: SPYRAL HTN-OFF MED PIVOTAL TRIAL RESULTS

F Sharif, B McGrath, T O’Connor, M Boehm, K Fario, D Kandzari, F Mahfoud, R Cusack.
Galway University Hospital, Galway, Ireland

Objective The SPYRAL HTN-OFF MED Pivotal Trial was designed to assess the efficacy of renal denervation (RDN) to lower blood pressure (BP) in the absence of anti-hypertensive medications.

Methods In this international, randomized, sham-controlled trial, patients with hypertension and office systolic blood pressure (SBP) ≥150 mmHg and <180 mmHg were randomised 1:1 to RDN or sham control. Patients were required to abstain from anti-hypertensive medications prior to randomization. The primary efficacy endpoint was baseline-adjusted change in 24-hour SBP from baseline to 3 months. The secondary efficacy endpoint was baseline-adjusted change in office SBP from baseline to 3 months. Bayesian statistics were used to utilize evidence from the pilot and pivotal studies.
CORRELATION OF INCIDENTAL LEFT ATRIAL HEART FAILURE PATIENT AND CAREGIVER NEEDS AND EXPECTATIONS REGARDING SELF-MANAGEMENT VIA DIGITAL HEALTH – THE PASSION-HF PROJECT

M Waters, C O’Connor, D Moore, B Loo. Tallaght University Hospital, Dublin, Ireland

Background Transoesophageal echocardiography is recognized as the gold standard for detection of a left atrial appendage (LAA) thrombus. LAA thrombus is visualized as filling defect on computed tomography (CT), however it can be difficult to differentiate between slow flow and thrombus. This poses challenges in both the reporting and interpretation of left atrial filling defects on non-cardiac gated CTs, and whether to classify this as thrombus or an issue with imaging technique when reporting. Due to the risk of stroke with a LAA thrombus, the reporting of a LAA thrombus on CT makes it difficult for physicians to ignore and usually leads to anti-coagulation, thereby exposing the patient to the risk of bleeding. In this study we assessed the correlation between left atrial appendage thrombus or filling defects on a non-cardiac gated CT, with confirmation on TOE.

Methods We retrospectively analyzed TOE cases performed at our center between March 2016 and March 2020. Patients were included if they had been referred for LAA assessment following identification of a suspected LAA thrombus on CT thorax.

Results 757 TOEs were conducted at our center during the study period. This study includes 19 patients who were referred for TOE following incidental left atrial appendage thrombus on CT. Baseline characteristics include; mean age 69.5 years, male 68.4%, hypertensive 79%, history of atrial fibrillation 63.2%, on long-term anti-coagulation 63.2%, on anticoagulation following CT prior to TOE 89.5%, previous stroke 21%, median CHA2DS2-VASC 3. The mean time from CT to TOE was 16 days.

15.8% (n = 3/19) of the patients referred had evidence of a LAA thrombus on TOE. 66% (n = 2) of these patients had a history of prior stroke, the median CHA2DS2-VASC score was 5 and overall 50% of the patients in our cohort who had a history of stroke had a LAA thrombus at TOE. The mean peak LAA filling velocity was only mildly reduced at 37 cm/s, and 63% (n = 12) of LAA were windsock morphology. In the follow-up period from TOE to data collection, there was no reported subsequent strokes in the 19 patients analyzed, mean follow-up time 14 months.

Discussion In patients who have an incidental left atrial thrombus or filling defect reported on non-gated CT thorax, only a minority have a thrombus at TOE and it was no associated with subsequent stroke risk. A history of stroke or CHA2DS2-VASC of >5 conferred a higher probability of thrombus being present and we recommend that physicians take this into consideration when deciding on anti-coagulation. The LAA filling velocities were only mildly reduced and the radiographic findings are likely related to CT gating rather than an physiological process in the left atrium. Incidental LAA thrombus on CT correlates poorly with presence of thrombus on TOE, and if there is concern a TOE should be performed to assess for a thrombus.